Back to News
Market Impact: 0.3
Viva Biotech Reports H1 2026 Results, Revenue Rises 21% On CDMO Growth
Source: Nasdaq
Corporate EarningsCompany FundamentalsCorporate Guidance & Outlook
Viva Biotech reported interim results for the six months ended June 30, 2026, with revenue up 21% YoY. Growth was driven primarily by Langhua Pharmaceutical’s CDMO business and progress in commercial manufacturing advancement. Overall tone is cautiously positive, but the article is truncated and provides limited detail on profitability and outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VBIZF0.35
More News
- Why is SSP stock sliding today?
- Why is argenx stock rallying today?
- SSP shares fall 4% as N. America weighs on profit, cash flow below expectation
- US suspends Microsoft and Adobe from visa programme amid fraud claims
- China’s tax crackdown piles pressure on luxury brands as US spending falters
- Why a Starbucks takeover of Chipotle would — and wouldn't — make sense for both companies